Summary

Exist several components without relation since the chemical view point, they are capable of work with the estrogen receptor and produce profiles in vivo singulars (tabla 1). Composed with profiles in vivo characteristics of a "pure" antagonist (In example, ICI-164384) or an antagonist relatively "pure" (In example, 17-estradiol) represent the opposed external of the spectral of this classification. Between this two extremes finds MSRE, whose characteristic for its clinical selectivity and/or preclinical like total agonist or partial in certain weaving (In example, the bond), and as minimums antagonist or agonists in the reproductive weaves. Inside in this pharmacological class each MSRE is possible differentiate of additional form according the activity profiles in the reproductive weaves. The tamoxifemo, a MSRE of firts generation with antiestrogenical activity in the mammary weave, has therapetical utility in the mamma cancer. The raloxifeno, knows as MSRE of second generation, manifests selectivity also potentially useful in uterine weave. In accordance with that, the raloxifeno seems be a adequate pharmaco for treatment of post-Menopausical complications, including the osteoporosis and cardiovascular sickness. According to exists more advances in pharmacology and molecular biology of active agents on estrogenics recepts, will evolution other subclassifications of MSRE, moreover of a largest compression of the therapeutic utility of this new classes of estrogen compounds.